The GYMSSA trial: a prospective randomized trial comparing gastrectomy, metastasectomy plus systemic therapy versus systemic therapy alone

BACKGROUND: The standard of care for metastatic gastric cancer (MGC) is systemic chemotherapy which leads to a median survival of 6-15 months. Survival beyond 3 years is rare. For selected groups of patients with limited MGC, retrospective studies have shown improved overall survival following gastr...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Kerkar, Sid P, Kemp, Clinton D, Duffy, Austin, Kammula, Udai S, Schrump, David S, Kwong, King F, Quezado, Martha, Goldspiel, Barry R, Venkatesan, Aradhana, Berger, Ann, Walker, Melissa, Toomey, Mary Ann, Steinberg, Seth M, Giaccone, Guiseppe, Rosenberg, Steven A, Avital, Itzhak
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2009
Assuntos:
Study protocol
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC2803175/
https://ncbi.nlm.nih.gov/pubmed/20030854
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1745-6215-10-121
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados